Summary
Intra-tumoral cancer therapies involve the direct administration of antitumor agents into tumors, promoting localized tumor destruction, stimulating the release of tumor-associated antigens, and activating an immune response within the tumor microenvironment that may also generate systemic antitumor effects.
At present, the approved ITCT landscape comprises only three therapies: IMLYGIC (talimogene laherparepvec/T-VEC; Amgen), approved in the US and Europe in 2015; DELYTACT (teserpaturev/G47∆; Daiichi Sankyo), approved in Japan in 2021; and HENSIFY, approved in Europe in 2019.
Promising pipeline therapies include JNJ-1900/NBTXR3 (NANOBIOTIX/Johnson &...
